Crystal structure of 4,4-dimethyl-2-(trifluoromethyl)-4,5-dihydro-1H-imidazole, C6H9F3N2 by Musa Said, A. et al.
Z. Kristallogr. NCS 2019; 234(3): 579–580
A. Musa Said*, Ismail Warad*, O. Seraj Alzahrani, Abdelkader Zarrouk and Dieter Lentz*




Received December 14, 2018; accepted January 15, 2019; available
online February 4, 2019
Abstract
C6H9F3N2, monoclinic, P21/n (no. 14), a= 10.6224(9) Å,
b= 11.8639(9) Å, c= 13.3139(11) Å, β= 105.903(3)°,
V = 1613.6(2) Å3, Z= 8, Rgt(F)=0.0618, wRref(F2)=0.1629,
T= 102(2) K [1–3].
CCDC no.: 1884790
The crystal structure is shown in the figure. Tables 1 and 2
contain details on crystal structure and measurement condi-
tions and a list of the atoms including atomic coordinates and
displacement parameters.
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Table 1: Data collection and handling.
Crystal: Colourless block
Size: 0.40×0.20×0.18 mm
Wavelength: Mo Kα radiation (0.71073 Å)
µ: 0.13 mm−1
Diffractometer, scan mode: Bruker Venture Photon, φ and ω
θmax, completeness: 27.6°,>99%
N(hkl)measured, N(hkl)unique, Rint: 25043, 3722, 0.029
Criterion for Iobs, N(hkl)gt: Iobs > 2 σ(Iobs), 3126
N(param)refined: 211
Programs: Bruker [1], SHELX [2, 3]
Source of material
Stoichiometric amount of 2-methylpropane-1,2-diamine
(1.68 g, 19.06 mmol) was dissolved in 50 mL of dioxone in
one neck round bottom flask equipped with a reflux con-
denser and magnetic stirring bar. Ethyl 2,2,2-trifluoroacetate
(2.71 mL, 3.97 g, 38.12 mmol) was added dropwise and the
mixture was stirred at moderate heating (50 °C) overnight.
The solvent was completely removed and viscous colorless
product was obtained. The product was further purified by
distillation under reduced pressure (0.1 mm Hg, RT), (Yield
79%). M.P. 55−57 °C.
Experimental details
Hydrogen atoms were placed at the calculated positions and
included using a riding model with U iso(H)= 1.2Ueq or 1.5Ueq
of the adjacent non-hydrogen atom.
Comment
The development of imidazole-based molecules has speedily
increased recently, since it can be used extensively in medic-
inal chemistry as man-made drugs, agrochemicals, artificial
acceptors, biomimetic catalysts, supramolecular material [4–
6]. Several imidazole medicinal drugs have been used for
treatment of broad types of diseases, imidazole derivatives
demonstrated anti-inflammatory, analgesic, antiviral, anti-
tubercular, antimicrobial, antimalarial, anti-diabetic and
anticancer activity [7–10].
The molecule C6H9F3N2 crystallizes in the space group
P21/n. The asymmetric unit of the title structure contains
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Table 2: Fractional atomic coordinates and isotropic or equivalent
isotropic displacement parameters (Å2).
Atom x y z Uiso*/Ueq
C1 0.6367(2) 0.27964(17) 0.58791(15) 0.0254(4)
C2 0.73966(18) 0.44033(16) 0.63748(15) 0.0220(4)
C3 0.6742(2) 0.40100(18) 0.72269(16) 0.0281(4)
H3A 0.739069 0.395447 0.791899 0.034*
H3B 0.603163 0.452885 0.727600 0.034*
C4 0.5809(3) 0.1758(2) 0.52623(18) 0.0413(6)
C5 0.6921(2) 0.55617(19) 0.59481(18) 0.0333(5)
H5A 0.729385 0.574908 0.537231 0.050*
H5B 0.719890 0.612439 0.650379 0.050*
H5C 0.596356 0.555871 0.569313 0.050*
C6 0.8882(2) 0.4379(2) 0.67844(19) 0.0346(5)
H6A 0.916767 0.361909 0.703466 0.052*
H6B 0.916464 0.491723 0.736064 0.052*
H6C 0.927006 0.458485 0.622156 0.052*
C7 0.40653(17) 0.18527(15) 0.85401(14) 0.0181(4)
C8 0.22696(18) 0.08125(16) 0.77486(14) 0.0214(4)
C9 0.31326(19) 0.11170(18) 0.70118(15) 0.0241(4)
H9A 0.349257 0.042471 0.678059 0.029*
H9B 0.260652 0.152188 0.638705 0.029*
C10 0.49772(19) 0.25035(17) 0.94148(14) 0.0232(4)
C11 0.0969(2) 0.1437(2) 0.74606(18) 0.0326(5)
H11A 0.052868 0.132647 0.801053 0.049*
H11B 0.041604 0.114349 0.679815 0.049*
C12 0.2065(2) −0.04492(18) 0.78123(18) 0.0350(5)
H12A 0.291734 −0.082610 0.804080 0.053*
H12B 0.158469 −0.073403 0.712299 0.053*
H12C 0.156267 −0.060202 0.831429 0.053*
F1 0.6175(4) 0.08556(15) 0.57764(17) 0.1328(15)
F2 0.4514(2) 0.1738(2) 0.5063(2) 0.1104(11)
F3 0.6078(2) 0.16886(14) 0.43734(13) 0.0660(6)
F4 0.58725(15) 0.30726(13) 0.90982(10) 0.0436(4)
F5 0.56104(13) 0.18335(11) 1.01875(10) 0.0353(3)
F6 0.43133(14) 0.32464(12) 0.98252(11) 0.0413(4)
N1 0.69927(17) 0.35430(14) 0.55252(13) 0.0246(4)
H1N 0.567(3) 0.259(3) 0.706(2) 0.051(9)*
N2 0.6232(2) 0.2912(17) 0.68486(15) 0.0371(5)
H2N 0.283(3) 0.137(2) 0.928(2) 0.036(7)*
N3 0.31069(16) 0.12340(15) 0.87538(13) 0.0252(4)
N4 0.42054(16) 0.18443(13) 0.76162(12) 0.0207(3)
two independent molecules (figure), with a high similarity in
their structural parameters like bond lengths and angles. The
similarity of these two structures extends to their hydrogen-
bonding motifs. The molecules in the title structure are
connected via intermolecular hydrogen bonds, of N—H· · ·N
type (N2· · ·N4: 2.91 Å; N1· · ·N3′: 2.93 Å; ′ = 0.5 + x, 0.5 − y,
−0.5 + z).
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